Human Papillomavirus (HPV)

Beyond Ebola, keeping patients and health workers safe

Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.

Vaccine in National Immunization Programme Update

WHO, UNICEF, and partners, are in regular dialogue with countries to support effective preparations.

Click here to access the downloadable PowerPoint file from the WHO website or simply click on the image below to read updates on vaccine in national immunization programmes.


Give HPV vaccine to men who have sex with men, government told

Government advisers have said the HPV vaccine offered to girls aged 12 or 13 to help protect them against cervical cancer should also be available to men who have sex with men.
The Joint Committee on Vaccination and Immunisation (JCVI) recommends three doses for men aged up to 45 who attend clinics specialising in treating HIV and genitourinary conditions. There should be no lower age limit, it says.

Study: Teens More Apt to Complete HPV Vaccine Series When Given With Other Shots

Could partnering the human papilloma virus vaccine with other, less controversial vaccines lead to higher compliance and completion rates and, ultimately, a drop in certain cancer rates?

The science doesn’t support them, but Japanese anti-vaxxers are winning on HPV

TOKYO — Vaccines are a highly politicized subject in many countries. Just look at Donald Trump’s repeated claims in the Republican presidential race that childhood vaccinations cause autism.
In Japan, a vigorous debate is underway over the safety of vaccinations against HPV, a virus that can lead to cervical cancer. Opponents say the vaccines — which have been given to more than 80 million girls and women around the world in the past nine years — are dangerous and cause mobility problems that can sometimes be severe.

HPV Vaccine Myth: Good Talks Needed

When people hear about vaccine deniers — anti-vaxxers, to some — they most often think about parents who are refusing to vaccinate their children. But there’s another type of vaccine refusal, and it’s important that we not ignore that. Doctors sometimes promote the use of some vaccines with less enthusiasm than others. Sometimes, they don’t talk about them at all.


EU regulator finds no safety issues with GSK, Merck HPV vaccines

 European drug regulators have found no safety concerns linking GlaxoSmithKline's and Merck's cervical cancer vaccines with two conditions known as complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS).
Concluding a safety review on Wednesday, the European Medicines Agency said its Pharmacovigilance Risk Assessment Committee (PRAC) found that "evidence does not support a causal link between the vaccines and development of CRPS or POTS".

Study says doctors passively discourage HPV vaccines

Doctors may be inadvertently discouraging some parents from having their preteens vaccinated against human papillomavirus, according to a new study, which suggests clinicians often don’t recommend the vaccine strongly enough.
Many pediatricians and family physicians — who deliver the bulk of HPV vaccines — don’t appear to be using the same matter-of-fact approaches as they do when they urge parents to vaccinate their adolescents against meningococcal disease or to get tetanus, diphtheria and pertussis booster shots, it said.

Advaxis gets a whiplash after its upbeat assessment of PhII cancer vaccine data

After rounding up a long lineup of collaborations for its cancer vaccine axalimogene filolisbac (ADXS-HPV), Advaxis says that a small study for cervical cancer produced promising outcomes for a significant number of the 26 patients involved.
That assessment was initially spurned by the market, with the stock ($ADXS) plunging close to 30% before immediately bouncing back and hovering around even Thursday afternoon.

Advaxis reports 'encouraging' PhII cervical cancer vaccine data

Operating in a field that can leave patients with few options, Advaxis ($ADXS) rolled out data for its cervical cancer vaccine this week that represent a "meaningful step" for those afflicted, according to one expert.